Evidence map›Paper›PMID 38004480›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review.

Ghazala Muteeb, Md Tabish Rehman, Moayad Shahwan, Mohammad Aatif

Registry-linked trialAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07167173 (Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis), which is not on this map. Cited by 436 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
436citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07167173 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis

TypeobservationalSponsorHospital Italiano de Buenos AiresRan2025 to 2025Enrolled10,000ConditionsSepsis, Septic Shock
3 · Its place in the literature

Who cites it

436 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Global prevalence of fluoroquinolone resistance inFrontiers in cellular and infection microbiology · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. NIR-Assisted Multimodal Strategies for Enhanced Antibacterial Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  12. Adaptive Response ofAntibiotics (Basel, Switzerland) · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Integrating in vivo and in silico: a comprehensive study of Helix aspersa mucin's therapeutic properties.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  20. Article

376 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ghazala MuteebDepartment of Nursing, College of Applied Medical Science, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0002-3328-3559
Md Tabish RehmanDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11437, Saudi Arabia.ORCID 0000-0003-2341-900X
Moayad ShahwanCenter for Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman 346, United Arab Emirates.
Mohammad AatifDepartment of Public Health, College of Applied Medical Sciences, King Faisal University, Al-Ahsa 31982, Saudi Arabia.ORCID 0000-0002-1748-2160

Funding

King Faisal University xxx
6 · The paper itself

Abstract

Antibiotics have revolutionized medicine, saving countless lives since their discovery in the early 20th century. However, the origin of antibiotics is now overshadowed by the alarming rise in antibiotic resistance. This global crisis stems from the relentless adaptability of microorganisms, driven by misuse and overuse of antibiotics. This article explores the origin of antibiotics and the subsequent emergence of antibiotic resistance. It delves into the mechanisms employed by bacteria to develop resistance, highlighting the dire consequences of drug resistance, including compromised patient care, increased mortality rates, and escalating healthcare costs. The article elucidates the latest strategies against drug-resistant microorganisms, encompassing innovative approaches such as phage therapy, CRISPR-Cas9 technology, and the exploration of natural compounds. Moreover, it examines the profound impact of antibiotic resistance on drug development, rendering the pursuit of new antibiotics economically challenging. The limitations and challenges in developing novel antibiotics are discussed, along with hurdles in the regulatory process that hinder progress in this critical field. Proposals for modifying the regulatory process to facilitate antibiotic development are presented. The withdrawal of major pharmaceutical firms from antibiotic research is examined, along with potential strategies to re-engage their interest. The article also outlines initiatives to overcome economic challenges and incentivize antibiotic development, emphasizing international collaborations and partnerships. Finally, the article sheds light on government-led initiatives against antibiotic resistance, with a specific focus on the Middle East. It discusses the proactive measures taken by governments in the region, such as Saudi Arabia and the United Arab Emirates, to combat this global threat. In the face of antibiotic resistance, a multifaceted approach is imperative. This article provides valuable insights into the complex landscape of antibiotic development, regulatory challenges, and collaborative efforts required to ensure a future where antibiotics remain effective tools in safeguarding public health.

Indexed as

antibiotic resistancebacterial evolutionbacterial mutationdrug designinghorizontal gene transferpublic and agricultural health

Identifiers

PMID38004480
PMCPMC10675245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.